[{"id":"0e9bd26b-0254-4ab8-9cad-e1d2a53d9952","acronym":"PRESERVE-003","url":"https://clinicaltrials.gov/study/NCT05671510","created_at":"2023-01-04T14:58:53.390Z","updated_at":"2025-02-25T12:38:29.772Z","phase":"Phase 3","brief_title":"ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors","source_id_and_acronym":"NCT05671510 - PRESERVE-003","lead_sponsor":"OncoC4, Inc.","biomarkers":" LAG3 • CTLA4 • TIGIT","pipe":"","alterations":" ","tags":["LAG3 • CTLA4 • TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • gotistobart (BNT316)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 06/28/2023","start_date":" 06/28/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-24"},{"id":"72d8c724-8d53-4e69-afd5-a79ba1831075","acronym":"REMAIN","url":"https://clinicaltrials.gov/study/NCT06029270","created_at":"2023-09-08T20:10:10.653Z","updated_at":"2025-02-25T13:55:33.082Z","phase":"Phase 2","brief_title":"Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer","source_id_and_acronym":"NCT06029270 - REMAIN","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • LAG3","pipe":"","alterations":" ","tags":["PD-L1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • gemcitabine • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 07/15/2024","start_date":" 07/15/2024","primary_txt":" Primary completion: 04/30/2029","primary_completion_date":" 04/30/2029","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-02-20"},{"id":"c388e765-68a9-4c36-8000-4ede187305c8","acronym":"CA224-094","url":"https://clinicaltrials.gov/study/NCT04552223","created_at":"2021-01-18T21:45:58.107Z","updated_at":"2025-02-25T14:29:34.845Z","phase":"Phase 2","brief_title":"Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma","source_id_and_acronym":"NCT04552223 - CA224-094","lead_sponsor":"Jose Lutzky, MD","biomarkers":" LAG3 • CTLA4","pipe":"","alterations":" ","tags":["LAG3 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/10/2020","start_date":" 11/10/2020","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2026","study_completion_date":" 01/04/2026","last_update_posted":"2025-02-13"},{"id":"abcc9d45-86e5-4f8d-9765-fdc49b92af3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06028074","created_at":"2023-09-07T16:09:55.474Z","updated_at":"2025-02-25T15:20:49.574Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies","source_id_and_acronym":"NCT06028074","lead_sponsor":"Georgiamune Inc","biomarkers":" LAG3","pipe":"","alterations":" ","tags":["LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GIM-122"],"overall_status":"Recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 12/12/2023","start_date":" 12/12/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-12"},{"id":"cae2f24f-fcc5-4921-81fc-01d942260332","acronym":"RELATIVITY-060","url":"https://clinicaltrials.gov/study/NCT03662659","created_at":"2022-05-09T20:53:55.716Z","updated_at":"2025-02-25T16:44:27.386Z","phase":"Phase 2","brief_title":"An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers","source_id_and_acronym":"NCT03662659 - RELATIVITY-060","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" LAG3","pipe":"","alterations":" ","tags":["LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Opdualag (nivolumab/relatlimab-rmbw)"],"overall_status":"Completed","enrollment":" Enrollment 274","initiation":"Initiation: 10/16/2018","start_date":" 10/16/2018","primary_txt":" Primary completion: 08/27/2020","primary_completion_date":" 08/27/2020","study_txt":" Completion: 01/18/2024","study_completion_date":" 01/18/2024","last_update_posted":"2025-02-05"},{"id":"44b80189-528f-4f15-a751-b2fa0ad145eb","acronym":"PCR-MIB","url":"https://clinicaltrials.gov/study/NCT02662062","created_at":"2025-02-25T18:11:21.641Z","updated_at":"2025-02-25T18:11:21.641Z","phase":"Phase 2","brief_title":"Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT02662062 - PCR-MIB","lead_sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","biomarkers":" CD20 • CD8 • PD-1 • LAG3 • CD4 • ICOS • FOXP3","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD8 • PD-1 • LAG3 • CD4 • ICOS • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 07/11/2017","start_date":" 07/11/2017","primary_txt":" Primary completion: 05/12/2022","primary_completion_date":" 05/12/2022","study_txt":" Completion: 08/26/2024","study_completion_date":" 08/26/2024","last_update_posted":"2025-01-27"},{"id":"a8403343-eec1-4085-9e32-03e56835ac8f","acronym":"Immunecheck","url":"https://clinicaltrials.gov/study/NCT06777628","created_at":"2025-02-25T20:17:00.202Z","updated_at":"2025-02-25T20:17:00.202Z","phase":"","brief_title":"Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma","source_id_and_acronym":"NCT06777628 - Immunecheck","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" PD-1 • LAG3 • CTLA4 • TIGIT","pipe":"","alterations":" ","tags":["PD-1 • LAG3 • CTLA4 • TIGIT"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/15/2024","start_date":" 09/15/2024","primary_txt":" Primary completion: 10/15/2026","primary_completion_date":" 10/15/2026","study_txt":" Completion: 10/15/2028","study_completion_date":" 10/15/2028","last_update_posted":"2025-01-16"},{"id":"49dce72b-9d7c-4760-9f04-db0fc8e432e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06070012","created_at":"2023-10-06T14:11:25.919Z","updated_at":"2025-02-25T16:27:38.972Z","phase":"Phase 2","brief_title":"Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma","source_id_and_acronym":"NCT06070012","lead_sponsor":"Diwakar Davar","biomarkers":" LAG3 • CTLA4","pipe":" | ","alterations":" HLA-A*02:01","tags":["LAG3 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kimmtrak (tebentafusp-tebn)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 01/31/2025","start_date":" 01/31/2025","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2029","study_completion_date":" 11/30/2029","last_update_posted":"2025-01-06"},{"id":"aea0f58d-10bb-4911-b89f-8864936129e3","acronym":"CA224-056","url":"https://clinicaltrials.gov/study/NCT04080804","created_at":"2021-01-18T19:58:51.916Z","updated_at":"2025-02-25T14:28:37.614Z","phase":"Phase 2","brief_title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","source_id_and_acronym":"NCT04080804 - CA224-056","lead_sponsor":"Dan Zandberg","biomarkers":" TMB • LAG3","pipe":" | ","alterations":" CD8 positive","tags":["TMB • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/20/2019","start_date":" 12/20/2019","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-12-13"},{"id":"9b80d640-ac33-4411-ad4d-9614359a1e32","acronym":"","url":"https://clinicaltrials.gov/study/NCT02265536","created_at":"2025-07-19T14:00:09.317Z","updated_at":"2025-07-19T14:00:09.317Z","phase":"Phase 1","brief_title":"A Study of LY3022855 In Participants With Breast or Prostate Cancer","source_id_and_acronym":"NCT02265536","lead_sponsor":"Eli Lilly and Company","biomarkers":" CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • IL2 • ICOS • IL10 • CD14 • FOXP3 • IL1B","pipe":"","alterations":" ","tags":["CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • IL2 • ICOS • IL10 • CD14 • FOXP3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY3022855"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 11/03/2017","primary_completion_date":" 11/03/2017","study_txt":" Completion: 11/03/2017","study_completion_date":" 11/03/2017","last_update_posted":"2024-10-28"},{"id":"be8a2507-7795-446b-88e5-5aa233ecd75d","acronym":"KEYNOTE-F49","url":"https://clinicaltrials.gov/study/NCT05763004","created_at":"2023-03-10T15:01:24.930Z","updated_at":"2025-02-25T16:18:38.185Z","phase":"Phase 1","brief_title":"A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors","source_id_and_acronym":"NCT05763004 - KEYNOTE-F49","lead_sponsor":"ImmunOs Therapeutics AG","biomarkers":" PD-L1 • PD-1 • LAG3","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • IOS-1002"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-10-07"},{"id":"131edcdb-27c4-4090-85ed-cdfe17502f92","acronym":"","url":"https://clinicaltrials.gov/study/NCT03743766","created_at":"2021-01-18T18:20:12.816Z","updated_at":"2025-02-25T14:27:49.581Z","phase":"Phase 2","brief_title":"Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting","source_id_and_acronym":"NCT03743766","lead_sponsor":"John Kirkwood","biomarkers":" PD-1 • LAG3","pipe":" | ","alterations":" PD-1 expression • LAG3 expression","tags":["PD-1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression • LAG3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 03/29/2019","start_date":" 03/29/2019","primary_txt":" Primary completion: 07/03/2024","primary_completion_date":" 07/03/2024","study_txt":" Completion: 07/03/2024","study_completion_date":" 07/03/2024","last_update_posted":"2024-09-25"},{"id":"4f28ce0c-9a5a-4a61-b5dd-312c3d0839fe","acronym":"KEYNOTE-A10","url":"https://clinicaltrials.gov/study/NCT03058289","created_at":"2021-01-18T15:03:51.688Z","updated_at":"2025-02-25T14:37:17.876Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6","source_id_and_acronym":"NCT03058289 - KEYNOTE-A10","lead_sponsor":"Intensity Therapeutics, Inc.","biomarkers":" MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B","pipe":"","alterations":" ","tags":["MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • cisplatin/vinblastine/SHAO-FA (INT230-6)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 02/22/2023","study_completion_date":" 02/22/2023","last_update_posted":"2024-08-13"},{"id":"114d9c89-e0e5-473e-a324-f2022f9b4244","acronym":"","url":"https://clinicaltrials.gov/study/NCT04465643","created_at":"2021-01-18T21:27:49.677Z","updated_at":"2025-02-25T14:29:26.270Z","phase":"Phase 1","brief_title":"Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor","source_id_and_acronym":"NCT04465643","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20","pipe":"","alterations":" ","tags":["PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-06-21"},{"id":"aff3e72a-a029-43e5-b059-ba3db87de101","acronym":"","url":"https://clinicaltrials.gov/study/NCT05127824","created_at":"2021-11-19T12:53:43.443Z","updated_at":"2024-07-02T16:34:26.105Z","phase":"Phase 2","brief_title":"Autologous Dendritic Cell Vaccine in Kidney Cancer","source_id_and_acronym":"NCT05127824","lead_sponsor":"Jodi Maranchie","biomarkers":" ER • CD8 • PD-1 • IFNG • LAG3 • TIGIT • LAMP3 • GZMB • BTLA • CD31 • NRP1 • PECAM1 • ANXA5","pipe":"","alterations":" ","tags":["ER • CD8 • PD-1 • IFNG • LAG3 • TIGIT • LAMP3 • GZMB • BTLA • CD31 • NRP1 • PECAM1 • ANXA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • aDC1 vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/06/2023","start_date":" 07/06/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-06-14"},{"id":"c39317e9-2ffe-4fe5-b487-781ec7511b8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02923180","created_at":"2021-01-18T14:21:11.868Z","updated_at":"2024-07-02T16:34:25.763Z","phase":"Phase 2","brief_title":"Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer","source_id_and_acronym":"NCT02923180","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" AR • PD-1 • LAG3 • CD276 • HAVCR2 • TNFRSF9 • LAMP1","pipe":" | ","alterations":" CD276 expression • LAG3 expression • HAVCR2 expression • LAMP1 expression","tags":["AR • PD-1 • LAG3 • CD276 • HAVCR2 • TNFRSF9 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • LAG3 expression • HAVCR2 expression • LAMP1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enoblituzumab (MGA271)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/14/2017","start_date":" 02/14/2017","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-14"},{"id":"8d7085c4-b70c-4d81-8155-40e3a80cc9f5","acronym":"HEAT","url":"https://clinicaltrials.gov/study/NCT06014255","created_at":"2023-08-28T14:08:37.514Z","updated_at":"2024-07-02T16:34:27.119Z","phase":"Phase 2","brief_title":"Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer","source_id_and_acronym":"NCT06014255 - HEAT","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-1 • LAG3 • CD276 • TNFRSF9 • LAMP1","pipe":" | ","alterations":" PD-L1 expression • LAMP1 expression","tags":["PD-1 • LAG3 • CD276 • TNFRSF9 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • LAMP1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enoblituzumab (MGA271)"],"overall_status":"Recruiting","enrollment":" Enrollment 219","initiation":"Initiation: 02/16/2024","start_date":" 02/16/2024","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-06-11"},{"id":"4bbdcbf6-ccbf-4476-adeb-a48a0a44206f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05225363","created_at":"2022-02-05T18:29:53.670Z","updated_at":"2024-07-02T16:35:01.290Z","phase":"Phase 1","brief_title":"Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05225363","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD8 • PD-1 • LAG3 • PTPRC • CCR7 • CD27 • LAMP1","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["CD8 • PD-1 • LAG3 • PTPRC • CCR7 • CD27 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TAG72-CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 05/05/2022","start_date":" 05/05/2022","primary_txt":" Primary completion: 04/05/2026","primary_completion_date":" 04/05/2026","study_txt":" Completion: 04/05/2027","study_completion_date":" 04/05/2027","last_update_posted":"2024-05-23"},{"id":"03e89ab8-dacb-455b-84eb-7a4c304f5cfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06338657","created_at":"2024-03-29T14:40:53.948Z","updated_at":"2024-07-02T16:35:02.933Z","phase":"Phase 1","brief_title":"FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer","source_id_and_acronym":"NCT06338657","lead_sponsor":"University of Southern California","biomarkers":" PD-1 • BCL6 • LAG3 • CD38 • TIGIT • CCR7 • GZMB • BTLA • PRDM1 • CXCR3 • SIGLEC15","pipe":"","alterations":" ","tags":["PD-1 • BCL6 • LAG3 • CD38 • TIGIT • CCR7 • GZMB • BTLA • PRDM1 • CXCR3 • SIGLEC15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • nanoencapsulated paclitaxel (FID-007)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-05-17"},{"id":"38f71642-9963-4119-8080-8fd4152ee9d4","acronym":"NCI9922","url":"https://clinicaltrials.gov/study/NCT02581930","created_at":"2021-01-18T12:31:19.061Z","updated_at":"2024-07-02T16:35:02.824Z","phase":"Phase 2","brief_title":"Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma","source_id_and_acronym":"NCT02581930 - NCI9922","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • LAG3 • CTLA4 • ERBB4 • CD40","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF • LAG3 • CTLA4 • ERBB4 • CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/17/2016","start_date":" 08/17/2016","primary_txt":" Primary completion: 02/10/2018","primary_completion_date":" 02/10/2018","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-05-17"},{"id":"cf185d09-6b9d-475d-a594-2be60eaf333a","acronym":"CA209-587","url":"https://clinicaltrials.gov/study/NCT04204837","created_at":"2021-01-18T20:29:01.682Z","updated_at":"2025-02-25T14:28:56.134Z","phase":"Phase 2","brief_title":"Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin","source_id_and_acronym":"NCT04204837 - CA209-587","lead_sponsor":"Salzburger Landeskliniken","biomarkers":" PD-L1 • LAG3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 03/06/2017","start_date":" 03/06/2017","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-04-18"},{"id":"59a6af87-be5d-497a-be99-d20aceadb627","acronym":"","url":"https://clinicaltrials.gov/study/NCT05520294","created_at":"2022-08-29T13:03:21.061Z","updated_at":"2024-07-02T16:35:09.309Z","phase":"","brief_title":"Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma","source_id_and_acronym":"NCT05520294","lead_sponsor":"University of Colorado, Denver","biomarkers":" CD20 • CD8 • PD-1 • LAG3 • TIGIT • SOX10 • FOXP3","pipe":"","alterations":" ","tags":["CD20 • CD8 • PD-1 • LAG3 • TIGIT • SOX10 • FOXP3"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2024-04-17"},{"id":"a2f75d20-dee9-45ea-9554-ac58b3d9f48d","acronym":"MITRIC","url":"https://clinicaltrials.gov/study/NCT05286294","created_at":"2022-03-18T12:53:40.816Z","updated_at":"2024-07-02T16:35:11.349Z","phase":"Phase 2","brief_title":"Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders","source_id_and_acronym":"NCT05286294 - MITRIC","lead_sponsor":"Oslo University Hospital","biomarkers":" PD-L1 • MSI • LAG3","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["PD-L1 • MSI • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/28/2022","start_date":" 06/28/2022","primary_txt":" Primary completion: 03/31/2034","primary_completion_date":" 03/31/2034","study_txt":" Completion: 12/31/2034","study_completion_date":" 12/31/2034","last_update_posted":"2024-04-04"},{"id":"6003592e-c212-4e12-bf84-ded1b1c44edb","acronym":"CIME","url":"https://clinicaltrials.gov/study/NCT06346197","created_at":"2024-04-03T23:39:52.167Z","updated_at":"2024-07-02T16:35:11.577Z","phase":"Phase 3","brief_title":"Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas","source_id_and_acronym":"NCT06346197 - CIME","lead_sponsor":"Centre Leon Berard","biomarkers":" TMB • LAG3 • TIGIT","pipe":"","alterations":" ","tags":["TMB • LAG3 • TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 05/15/2024","start_date":" 05/15/2024","primary_txt":" Primary completion: 05/15/2028","primary_completion_date":" 05/15/2028","study_txt":" Completion: 05/15/2028","study_completion_date":" 05/15/2028","last_update_posted":"2024-04-03"}]